Skip to content

GeneSpect Reporter for
Pharmacogenomics

End-to-end pharmacogenomic interpretation, delivering evidence-based guidance ready to act on.

A cluster of pharmacogenes the platform reports on: CYP2C19, DPYD, HLA-B, SLCO1B1 and CYP2D6

About GeneSpect PGx Reporter

One analysis answers today's dosing question and becomes a reference that lasts a lifetime.

Every prescribing decision can be informed by understanding how genetic variation affects drug response and safety. GeneSpect PGx Reporter automates the entire pharmacogenomic pipeline - transforming raw sequencing data into clear, physician-ready reports. By resolving haplotypes and accurately calling star alleles, it delivers actionable insights in minutes, with interpretation informed by established pharmacogenomic guidelines and curated knowledge bases, including CPIC, DPWG, FDA, and PharmGKB. One analysis answers today’s dosing question - and provides a genomic reference that lasts a lifetime.

15

therapeutic areas

selectable at analysis time

45

pharmacogenes resolved

including CYP2D6 CNV detection

4000+

drugs evaluated

across FDA, CPIC, DPWG and PharmGKB

Two applications.One analysis.

REACTIVE TESTING

Immediate insight on active medications

Evaluate current therapy against the resolved genotype. Built-in decision support surfaces the risks that need attention now - and the alternatives worth considering.

A diamond of five connected nodes, representing the platform cross-referencing active medications against the resolved genotype

  • Immediate pharmacogenetic alerts where risk is identified

  • Evidence-backed alternatives where guidelines support them

  • Transparent flags for both unassociated drugs and out-of-panel targets

PREEMPTIVE TESTING

Lifelong guidance on every future prescription

Screen thousands of medications against the resolved genotype in advance. Each clinically significant gene-drug interaction is documented and ready - long before the prescription is written.

An hourglass inside a circular arrow, representing the genotype being screened in advance against future prescriptions

  • 4,000+ drugs pre-assessed against the genotype

  • 15 therapeutic areas, tailored to each case

  • Every significant interaction catalogued for future reference

Workflow features

The analytical depth behind everyrecommendation

Any input, any assay

Targeted qPCR, amplicon-based NGS and whole-exome sequencing are all supported - entering the workflow as raw FASTQ or as data already processed upstream.

  • qPCR
  • NGS panel
  • WES
  • FASTQ file
  • VCF file
  • TXT file
  • XLSX file

Clinical decision support

Medications already in use come first, with alerts attached

Every drug currently prescribed is checked against the resolved genotype first. Significant interactions surface as pharmacogenetic alerts, each resolved into a single action label that can be acted on immediately - with supported alternatives attached where a change is advised. Medications outside the panel's capture scope are declared rather than silently omitted.

  • NO ASSOCIATION

    No PGx association

    Genotype and phenotype are known, but current evidence does not support any genotype-based change to prescribing for this drug

  • CRITICAL ALERT

    Consider alternatives

    The detected genotype is associated with a clinically relevant risk that may require an alternative therapy or modified treatment approach, based on applicable clinical guidelines.

  • WARNING

    Use with caution

    The genotype changes how the drug is metabolised without ruling it out - safe use depends on dose adjustment or added monitoring.

  • STANDRAD

    Standrad dosing

    The genotype represents standard functional activity at the evaluated locus. Normal prescribing protocols and manufacturer dosing apply.

The final report

Written for the decision at hand,kept for the decades after it.

GeneSpect PGx Reporter delivers an actionable, physician-ready report - structured for immediate clinical use, adaptable to each laboratory's requirements through white-label branding and custom configuration, and signed off directly from the iFlow Platform.

Current medication alert

Active therapy assessed first, each drug with its action label and supported alternatives.

Preemptive medication overview

Over 4,000 drugs assessed across 15 selectable therapeutic areas, with full recommendations wherever a critical label applies.

Pharmacogenetic test summary

Every pharmacogene with its resolved diplotype and phenotype, split across pharmacokinetic and pharmacodynamic profiles.

Coverage appendix

Regions with insufficient depth or inconclusive calls, documented as the rationale behind any result.

See how GeneSpect PGx can simplify analysis and reporting for your laboratory.

GeneSpect PGxReporter Resources

View all